WO2007014671A3 - KOMBINATIONEN MIT IKK-ß INHIBITOREN - Google Patents

KOMBINATIONEN MIT IKK-ß INHIBITOREN Download PDF

Info

Publication number
WO2007014671A3
WO2007014671A3 PCT/EP2006/007299 EP2006007299W WO2007014671A3 WO 2007014671 A3 WO2007014671 A3 WO 2007014671A3 EP 2006007299 W EP2006007299 W EP 2006007299W WO 2007014671 A3 WO2007014671 A3 WO 2007014671A3
Authority
WO
WIPO (PCT)
Prior art keywords
ikk
beta inhibitors
combinations containing
containing ikk
beta
Prior art date
Application number
PCT/EP2006/007299
Other languages
English (en)
French (fr)
Other versions
WO2007014671A2 (de
Inventor
Olaf Weber
Karl Ziegelbauer
Peter Seiler
Thomas Krahn
Nicole Diedrichs
Bernd Riedl
Original Assignee
Bayer Healthcare Ag
Olaf Weber
Karl Ziegelbauer
Peter Seiler
Thomas Krahn
Nicole Diedrichs
Bernd Riedl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005036656A external-priority patent/DE102005036656A1/de
Application filed by Bayer Healthcare Ag, Olaf Weber, Karl Ziegelbauer, Peter Seiler, Thomas Krahn, Nicole Diedrichs, Bernd Riedl filed Critical Bayer Healthcare Ag
Priority to EP06776386A priority Critical patent/EP1912646A2/de
Priority to CA002617692A priority patent/CA2617692A1/en
Priority to JP2008524397A priority patent/JP2009502996A/ja
Publication of WO2007014671A2 publication Critical patent/WO2007014671A2/de
Publication of WO2007014671A3 publication Critical patent/WO2007014671A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Anmeldung betrifft die Verwendung eines IKK-beta Inhibitors durch Herstellung von Arzneimitteln zur Behandlung von Tumoren, sowie Arzneimittel enthaltend diesen IKK-beta Inhibitor.
PCT/EP2006/007299 2005-08-04 2006-07-25 KOMBINATIONEN MIT IKK-ß INHIBITOREN WO2007014671A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06776386A EP1912646A2 (de) 2005-08-04 2006-07-25 KOMBINATIONEN MIT IKK-ß INHIBITOREN
CA002617692A CA2617692A1 (en) 2005-08-04 2006-07-25 Combinations containing ikk-.beta. inhibitors
JP2008524397A JP2009502996A (ja) 2005-08-04 2006-07-25 ＩＫＫ−β阻害剤との組合せ

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102005036656.2 2005-08-04
DE102005036656A DE102005036656A1 (de) 2005-08-04 2005-08-04 Kombinationen mit IKK-ß Inhibitoren
DE102005036657.0 2005-08-04
DE102005036657 2005-08-04

Publications (2)

Publication Number Publication Date
WO2007014671A2 WO2007014671A2 (de) 2007-02-08
WO2007014671A3 true WO2007014671A3 (de) 2007-08-16

Family

ID=37708965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007299 WO2007014671A2 (de) 2005-08-04 2006-07-25 KOMBINATIONEN MIT IKK-ß INHIBITOREN

Country Status (4)

Country Link
EP (1) EP1912646A2 (de)
JP (1) JP2009502996A (de)
CA (1) CA2617692A1 (de)
WO (1) WO2007014671A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876984B (zh) * 2015-05-20 2017-10-03 武汉大学 一株高产洋橄榄叶素类化合物的菌株及该类化合物的制备方法与应用
CN111991410B (zh) * 2020-09-21 2021-08-06 中国医学科学院医药生物技术研究所 洋橄榄叶素衍生物在制备抗肿瘤药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094322A2 (en) * 2001-05-24 2002-11-28 Leo Pharma A/S Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094322A2 (en) * 2001-05-24 2002-11-28 Leo Pharma A/S Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents

Also Published As

Publication number Publication date
EP1912646A2 (de) 2008-04-23
WO2007014671A2 (de) 2007-02-08
CA2617692A1 (en) 2007-02-08
JP2009502996A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
IL191997A0 (en) Inhibitors of iap
IL184303A0 (en) Amino-pyridines as inhibitors of ??-secretase
HK1100930A1 (en) Inhibitors of iap iap
IL179854A0 (en) Inhibitors of iap
EP2497470B8 (de) Imidazotriazine und Imidazopyrimidine als Kinasehemmer
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
WO2007115821A3 (en) Organic compounds
WO2007054623A3 (en) Mammalian hedgehog signaling inhiabitors
ZA200608221B (en) Thiadlazolidinones as GSK-3 Inhibitors
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
PL2057153T3 (pl) POCHODNE (3-ARYLO-PIPERAZYN-1-YLOWE) 6,7-DIALKOKSYCHINAZOLINY, 6,7-DIALKOKSYFTALAZYNY i 6,7-DIALKOKSYIZOCHINOLINY
EP1863769A4 (de) Hsp90-inhibitoren, verfahren zu deren herstellung und deren anwendungen
AU2007312310A1 (en) Phenylacetamides useful as protein kinase inhibitors
AU2008203254A1 (en) Compositions of phosphodiesterase type IV inhibitors
WO2007067784A3 (en) Liposomal compositions
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
EP1967210A4 (de) Neue anwendung von apelin
WO2007014671A3 (de) KOMBINATIONEN MIT IKK-ß INHIBITOREN
WO2007070494A3 (en) Heterocycles and derivatives thereof and methods of manufacture and therapeutic use
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases
AU2005905465A0 (en) Method of Drug Design
AU2005905580A0 (en) Replication of Object Graphs
HU0500461D0 (en) Pyperazinyl derivatives of alkyl-oxindoles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006776386

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2617692

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008524397

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006776386

Country of ref document: EP